[EN] TRICYCLIC PYRIDINE DERIVATIVES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR PREPARATION [FR] DÉRIVÉS DE PYRIDINES TRICYCLIQUES, MÉDICAMENTS CONTENANT CES COMPOSÉS, LEUR UTILISATION ET LEUR PROCÉDÉ DE PRÉPARATION
Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
申请人:Wagner Holger
公开号:US08703793B2
公开(公告)日:2014-04-22
Compounds of formula (I) wherein the groups R1 to R8 have the meanings indicated in the description, the tautomers, the stereoisomers, the mixtures thereof and the salts thereof have valuable pharmacological properties, which make them useful for the treatment of cardiovascular and related disorders.
The present invention is intended to provide a compound or a pharmacologically acceptable salt thereof which has an excellent inhibitory action on the ATPase activity of a TIP48/TIP49 complex and as such, is useful for the treatment of tumors.
[Solution]
The present invention provides a compound having a structure represented by the general formula (I) or a pharmacologically acceptable salt thereof, and a pharmaceutical composition comprising the compound. In the formula, R1, R2, R3, R4, R5, R6, R7, and W are as defined in the present specification.
本发明旨在提供一种化合物或其药理学上可接受的盐,该化合物或其药理学上可接受的盐对 TIP48/TIP49 复合物的 ATPase 活性具有极佳的抑制作用,因此可用于治疗肿瘤。
[解决方案]
本发明提供了一种具有通式(I)所代表结构的化合物或其药理学上可接受的盐,以及包含该化合物的药物组合物。式中,R1、R2、R3、R4、R5、R6、R7 和 W 如本说明书中所定义。
Mutant IDH1 inhibitors useful for treating cancer
申请人:THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE
公开号:US10703746B2
公开(公告)日:2020-07-07
Compounds of Formula I and Formula II and the pharmaceutically acceptable salts thereof are disclosed The variables A, B, Y, Z, X1, X2, R1-4 and R13-18 are disclosed herein. The compounds are useful for treating cancer disorders, especially those involving mutant IDH1 enzymes. Pharmaceutical compositions containing compounds of Formula I or Formula II and methods of treatment comprising administering compounds of Formula I and Formula II are also disclosed.
公开了式 I 和式 II 的化合物及其药学上可接受的盐 本文公开了变量 A、B、Y、Z、X1、X2、R1-4 和 R13-18。这些化合物可用于治疗癌症疾病,特别是涉及突变 IDH1 酶的疾病。还公开了含有式 I 或式 II 化合物的药物组合物以及包括施用式 I 和式 II 化合物的治疗方法。
Pyrazole derivatives as MALT1 inhibitors
申请人:Janssen Pharmaceutica NV
公开号:US10954214B2
公开(公告)日:2021-03-23
Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) as follows:
wherein R1, R2, R3, R4, R5, R6, R5, G1, and G2 are defined herein.